What is the prevalence of Aniridia?

The estimated global prevalence of congenital Aniridia is approximately 1 in 40,000 to 1 in 100,000 individuals, though these figures vary by region and diagnostic criteria.

Epidemiological Overview

Aniridia is classified as a rare disease. Because it is primarily a genetic condition caused by mutations in the PAX6 gene, it is present at birth, making it a pediatric-onset condition that persists throughout the patient's lifetime. The incidence of new cases is relatively stable, as it typically follows an autosomal dominant inheritance pattern; however, spontaneous mutations also occur, leading to isolated cases within families.

Demographics and Variations

Current clinical literature indicates that Aniridia affects males and females with equal frequency, showing no significant gender bias. While the condition is found globally, some studies suggest slight variations in prevalence reporting, often influenced by the quality of national health registries rather than true ethnic predilection. It is important to note that the term "rare" is used here, as the condition does not reach the threshold of "common" population health metrics.

Challenges in Data Accuracy

Accurate prevalence data for Aniridia is notoriously difficult to capture. Underdiagnosis and misdiagnosis are common, particularly in cases where the iris hypoplasia is subtle or overshadowed by secondary complications like glaucoma, cataracts, or foveal hypoplasia. Many patients may be diagnosed with secondary ocular issues without the underlying Aniridia being formally documented in public health databases.

Community Perspective

While formal clinical registries provide the foundation for our understanding, the 228 members of the DiseaseMaps.org Aniridia community offer a vital, real-world perspective. These patient-reported experiences highlight the lived reality of the condition, supplementing clinical data by capturing the diagnostic journey and the long-term management challenges faced by families worldwide.

Medical Disclaimer: This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your ophthalmologist or genetic counselor regarding your specific health condition.

References

• Orphanet: Congenital Aniridia (ORPHA:81)


• NIH Genetic and Rare Diseases Information Center (GARD): Aniridia


• OMIM (Online Mendelian Inheritance in Man): Aniridia Type I (#106200)